New Medication Release of Tonmya

The FDA has approved Tonmya (cyclobenzaprine HCl sublingual tablet) for the treatment of fibromyalgia in adults, making it the first new FDA-approved treatment for the disease in more than 15 years.

Tonmya is indicated to treat fibromyalgia to help reduce pain, improve sleep quality, and relieve fatigue.

Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual (under the tongue) formulation that is designed for rapid absorption into the bloodstream.

Tonmya sublingual tablets are manufactured by Tonix Pharmaceuticals Holding Corp. and contain 2.8mg of cyclobenzaprine hydrochloride.

The anticipated availability of Tonmya for patients is in the fourth quarter of 2025.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.

The post New Medication Release of Tonmya appeared first on Carlisle Medical.